Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation

AIM: To determine effect of irritable bowel syndrome(IBS) subtype on IBS-specific quality of life(QOL) questionnaire and its subscales.METHODS: We studied IBS patients visiting our functional gastroenterology disorder clinic at a tertiary care center of Unites States.IBS and IBS subtype were diagnosed using Rome-Ⅲ questionnaire.QOL was assessed using IBS-QOL questionnaire.IBSQOL assesses quality of life along eight subscales: dysphoria,interference with activities,body image,health worry,food avoidance,social reactions,sexual health,and effect on relationships.IBS-QOL and its subscales were both scored on a range of 0-100 with higher scores suggestive of better QOL.Results of overall IBS-QOL scores and subscale scores are expressed as means with 95%CI.We compared mean IBS-QOL score and its subscales among various IBSsubtypes.Analysis of variance(ANOVA) was used to compare the mean difference between more than two groups after controlling for age and gender.A posthoc analysis using Bonferroni correction was used only when P value for ANOVA was less than 0.05.RESULTS: Of 542 patients screened,243 had IBS as per Rome-Ⅲ criteria.IBS-mixed(IBS-M) was the most common IBS subtype(121 patients,49.8%) followed by IBS- diarrhea(IBS-D)(56 patients,23.1%),IBSconstipation(IBS-C)(54 patients,22.2%) and IBSunspecified(IBS-U)(12 patients,4.9%).Overall IBSQOL scores were significantly different among various IBS-subtypes(P = 0.01).IBS-QOL of patients with IBS-D(61.6,95%CI: 54.0-69.1) and IBS-M(63.0,95%CI: 58.1-68.0) was significantly lower than patients with IBS-C(74.5,95%CI: 66.9-82.1)(P = 0.03 and 0.02 respectively).IBS-D patients scored significantly lower than IBS-C on food avoidance(45.0,95%CI: 34.8-55.2 vs 61.1,95%CI: 50.8-71.3,P = 0.04) and interference with activity(59.6,95%CI: 51.4-67.7 vs 82.3,95%CI: 74.1-90.6,P < 0.001).IBS-M patients had more interference in their activities(61.6,95%CI: 56.3-66.9 vs 82.3,95%CI: 74.1-90.6,P = 0.001) and greater impact on their relationships(73.3,95%CI: 68.4-78.2 vs 84.7,95%CI: 77.2-92.2,P = 0.02) than IBS-C patients.Patients with IBS-M also scored significantly lower than IBS-C on food avoidance(47.2,95%CI: 40.7-53.7 vs 61.1,95%CI: 50.8-71.3,P = 0.04) and social reaction(66.1,95%CI: 61.1-71.1 vs 80.0,95%CI: 72.1-87.7,P = 0.005).CONCLUSION: IBS-D and IBS-M patients have lower IBS-QOL than IBS-C patients.Clinicians should recognize food avoidance,effects on daily activities and relationship problems in these patients.

I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life

AIM:To determine the dose-related effects of a novel probiotic combination,I.31,on irritable bowel syndrome(IBS)-related quality of life(IBS-QoL).METHODS:A multicenter,randomized,double-blind,placebo-controlled intervention clinical trial with three parallel arms was designed.A total of 84 patients(53female,31 male;age range 20-70 years)with IBS and diarrhea according to Rome-Ⅲcriteria were randomly allocated to receive one capsule a day for 6 wk containing:(1)I.31 high dose(n=28);(2)I.31 low dose(n=27);and(3)placebo(n=29).At baseline,and 3and 6 wk of treatment,patients filled the IBSQoL,Visceral Sensitivity Index(VSI),and global symptom relief questionnaires.RESULTS:During treatment,IBS-QoL increased in all groups,but this increment was significantly larger in patients treated with I.31 than in those receiving placebo(P=0.008).After 6 wk of treatment,IBS-QoL increased by 18±3 and 22±4 points in the high and the low dose groups,respectively(P=0.041 and P=0.023vs placebo),but only 9±3 in the placebo group.Gutspecific anxiety,as measured with VSI,also showed a significantly greater improvement after 6 wk of treatment in patients treated with probiotics(by 10±2 and14±2 points,high and low dose respectively,P<0.05for both vs 7±1 score increment in placebo).Symptom relief showed no significant changes between groups.No adverse drug reactions were reported following the consumption of probiotic or placebo capsules.CONCLUSION:A new combination of three different probiotic bacteria was superior to placebo in improving IBS-related quality of life in patients with IBS and diarrhea.

Effect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome

BACKGROUND Bifidobacterium longum 35624 has shown efficacy in improving irritable bowel syndrome(IBS)symptoms compared with placebo in double-blind randomized studies.However,few data are available from real-life clinical practice or from studies that used Rome IV criteria to diagnose IBS.AIM To assess the effect of B.longum 35624 on IBS severity and quality of life in a reallife setting.METHODS From November 2018 to January 2020,278 patients with IBS(according to Rome IV criteria)were enrolled in a prospective,open-label,multicenter observational study by private practice gastroenterologists to received one capsule of B.longum 35624(10^(9) colony-forming units)per day for 30 d.Participation in the study was independently proposed to patients during spontaneous consultations.Disease severity(assessed by the IBS severity scoring system)and patient quality of life(assessed by the IBS quality of life questionnaire)were compared between the inclusion visit(baseline)and the visit at the end of 30 d of treatment.The characteristics of patients were described at baseline.Continuous variables comparisons between inclusion and end-of-treatment visits were performed using the t-test and Kruskal-Wallis test.Categorical variables comparisons were performed using theχ^(2) test.RESULTSA total of 233 patients,with a mean age of 51.4 years and composed of 71.2%women,were included in the study.Of these patients,48.1%had moderate IBS and 46.4%had severe IBS.After a 30-d treatment period with one B.longum 35624 capsule per day,a significant decrease in IBS severity was observed compared to baseline(mean±SD,IBS severity scoring system scores:208±104 vs 303±81,P<0.001)and 57%of patients moved to lower severity categories or achieved remission.The quality of life of patients was also improved by the treatment(IBS Quality of Life questionnaire score:68.8±20.9 vs 60.2±20.5;P<0.001)and 63.8%of patients were satisfied with the treatment.CONCLUSION Thirty days of treatment with B.longum 35624 reduces disease severity and improves the quality of life of patients with IBS,particularly those with the most severe forms of IBS.

Age-related symptom and life quality changes in women with irritable bowel syndrome

AIM:To explore age-related changes in symptoms and quality of life(QoL) of women with irritable bowel syndrome(IBS).METHODS:Two-hundred and fifty-four female adult outpatients with IBS attending the Department of Gastroenterology at the First Affiliated Hospital of Nanjing Medical University between January,2008 and October,2008 were approached.Patients with a history of abdominal surgery,mental illness or those who had recently taken psychotropic drugs were excluded.A physician obtained demographic and abdominal symptom data.All patients were asked to complete the Zung Self-Rated Anxiety and Depression Scale(SDS/SAS) and the IBS-specific QoL questionnaire.The patients were divided into six groups according to age,in 10-year increments:18-27 years,28-37 years,38-47 years,48-57 years,58-67 years and 68-75 years(maximum 75 years).Age-related differences of abdominal pain or discomfort were analyzed using ranksum tests.Differences in SDS/SAS and IBS-QoL scores between age groups were analyzed using one-way analysis of variance.Pearson's correlations evaluated potential associations between IBS symptoms,psychological factors and QoL in each age group.RESULTS:There were no differences in the distribution of IBS subtypes between age groups(χ2 = 20.516,P = 0.153).Differences in the severity of abdominal pain/discomfort with age were statistically significant(χ2 = 25.638,P < 0.001);patients aged 48-57 years,58-67 years or 68-75 years had milder abdominal pain/discomfort than those in the younger age groups.The severity of anxiety or depressive symptoms did not differ between age groups(SDS,χ2 = 390.845,P = 0.110;SAS,χ 2 = 360.071,P = 0.220).Differences of IBSQoL scores were statistically significant between age groups(χ2 = 1098.458,P = 0.011).The scores of patients in the 48-57-year group were lower than those in the 18-27-year and 28-37-year groups(48-57-year group vs 18-27-year group,74.88 ± 8.76 vs 79.76 ± 8.63,P = 0.021;48-57-year group vs 28-37-year group,74.88 ± 8.76 vs 79.04 ± 8.32,P = 0.014).The scores in the 68-75-year group were lower than those in the 18-27-year,28-37-year and 38-47-year groups(68-75-year group vs 18-27-year group,71.98 ± 9.83 vs 79.76 ± 8.63,P = 0.003;68-75-year group vs 28-37-year group,71.98 ± 9.83 vs 79.04 ± 8.32,P = 0.002;68-75-year group vs 38-47-year group,71.98 ± 9.83 vs 76.44 ± 8.15,P = 0.039).Anxiety and depression were negatively correlated with QoL in all age groups(SDS and QoL:18-27-year group,r =-0.562,P = 0.005;28-37-year group,r =-0.540,P < 0.001;38-47-year group,r =-0.775,P < 0.001;48-57-year group,r =-0.445,P = 0.001;58-67-year group,r =-0.692,P < 0.001;68-75-year group,r =-0.732,P < 0.001.SAS and QoL:18-27-year group,r =-0.600,P = 0.002;28-37-year group,r =-0.511,P < 0.001;38-47-year group,r =-0.675,P < 0.001;48-57-year group,r =-0.558,58-67-year group,P = 0.001;r =-0.588,P < 0.001;68-75-year group,r =-0.811,P < 0.001).A negative correlation between abdominal pain severity and QoL was found in patients aged more than 58 years(58-67-year group,r =-0.366,P = 0.017;68-75-year group,r =-0.448,P = 0.048),but not in younger patients(18-27-year group,r = 0.080,P = 0.716;28-37-year group,r =-0.063,P = 0.679;38-47-year group,r =-0.029,P = 0.812;48-57-year group,r =-0.022,P = 0.876).CONCLUSION:Factors affecting QoL should always be treated in IBS,especially emotional problems in young adults.Even mild abdominal pain should be controlled in elderly patients.

Irritable bowel syndrome symptom severity improves equally with probiotic and placebo

AIM To determine the effects of Lactobacillus acidophilus NCFM on irritable bowel syndrome(IBS) symptoms and quality of life(Qo L).METHODS In this randomized triple-blind trial, adult IBS volunteerswho were recruited according to Rome Ⅲ criteria received 109 or 1010 colony-forming units of NCFM or placebo daily for 12 wk. IBS Symptom Severity Score(IBS-SSS), which constituted the primary outcome, and secondary outcomes, including individual IBS symptoms, IBS-related QoL questionnaire, anxiety and depression, defecation frequency, and stool consistency, were assessed at baseline at the end of the 8-wk runin period, after 4 and 12 wk of intervention, and after a 4-wk washout.RESULTS A total of 340 of 391 randomized volunteers completed the trial. IBS-SSS improved over 12 wk of treatment in all treatment groups, decreasing by a mean ± SD of 44.0 ± 80.2, 50.8 ± 82.4, and 48.3 ± 72.2 in the placebo, active low-dose, and active high-dose groups, respectively. Similarly, secondary outcomes did not differ between treatment groups. However, in a post hoc analysis of volunteers with moderate to severe abdominal pain at baseline(VAS > 35/100), the treatment significantly reduced the sensation of abdominal pain. Pain scores fell by 20.8 ± 22.8, 29.4 ± 17.9, and 31.2 ± 21.9 in the placebo, active low-dose, and active high-dose groups, respectively(P value for placebo vs combined active doses = 0.0460).CONCLUSION NCFM alleviates moderate to severe abdominal pain, consistent with earlier observations of this strain mitigating visceral pain through increased analgesic receptor expression.

psychosocial impact of irritable bowel syndrome: A brief review

Irritable bowel syndrome(IBS) is a common disorder of the gastrointestinal tract with unclear etiology and no reliable biomarker. Like other chronic and functional disorders, medical treatments for IBS are suboptimal and the overall illness burden is high. Patients with IBS report high rates of psychopathology, low quality of life, and increased suicidal ideation. These patients also miss more days of work, are less productive at work, and use many healthcare resources. However, little is known about the burden of IBS on daily functioning. The primary aim of this paper is to review the current literature on the burden of IBS and to highlight the need for further research to evaluate the impact of IBS on daily activities. This research would contribute to our existing understanding of the impact of IBS on overall quality of life and well-being.

Ehealth:Low FODMAP diet vs Lactobacillus rhamnosus GG in irritable bowel syndrome

AIM:To investigate the effects of a low fermentable,oligosaccharides,disaccharides,monosaccharides and polyols diet(LFD)and the probiotic Lactobacillus rhamnosus GG(LGG)in irritable bowel syndrome(IBS).METHODS:Randomised,unblinded controlled trial on the effect of 6-wk treatment with LFD,LGG or a normal Danish/Western diet(ND)in patients with IBS fulfilling Rome III diagnostic criteria,recruited betweenNovember 2009 and April 2013.Patients were required to complete on a weekly basis the IBS severity score system(IBS-SSS)and IBS quality of life(IBS-QOL)questionnaires in a specially developed IBS web selfmonitoring application.We investigated whether LFD or LGG could reduce IBS-SSS and improve QOL in IBS patients.RESULTS:One hundred twenty-three(median age 37years,range:18-74 years),90(73%)females were randomised:42 to LFD,41 to LGG and 40 to ND.A significant reduction in mean±SD of IBS-SSS from baseline to week 6 between LFD vs LGG vs ND was revealed:133±122 vs 68±107,133±122 vs 34±95,P<0.01.Adjusted changes of IBS-SSS for baseline covariates showed statistically significant reduction of IBS-SSS in LFD group compared to ND(IBS-SSS score75;95%CI:24-126,P<0.01),but not in LGG compared to ND(IBS-SSS score 32;95%CI:18-80,P=0.20).IBS-QOL was not altered significantly in any of the three groups:mean±SD in LFD 8±18 vs LGG 7±17,LFD 8±18 vs ND 0.1±15,P=0.13.CONCLUSION:LFD is efficacious for patients with IBS.

Saccharomyces cerevisiae I-3856 in irritable bowel syndrome with predominant constipation

BACKGROUND Probiotics are a promising solution for managing irritable bowel syndrome(IBS).Saccharomyces cerevisiae(S.cerevisiae)I-3856 has already demonstrated beneficial effects in IBS subjects,particularly in IBS with predominant constipation(IBS-C).AIM To confirm the efficacy of S.cerevisiae I-3856 in the management of gastrointestinal symptoms in IBS-C.METHODS A randomized,double-blind,placebo-controlled clinical study was performed in a total of 456 subjects.After a run-in period,subjects were randomly assigned to the group receiving S.cerevisiae I-3856(8×109 CFU daily)or the placebo for 8 wk,and they performed daily self-evaluations of gastrointestinal symptoms.The primary objective was to assess the effect of the probiotic on abdominal pain.The secondary objectives were the evaluation of other gastrointestinal symptoms,bowel movement frequency and consistency,and quality of life(QOL).RESULTS A significantly higher proportion of abdominal pain responders was reported in the Probiotic group(45.1%vs 33.9%,P=0.017).A nonsignificant difference in the area under the curve for abdominal pain over the second month of supplementation was observed in subjects receiving probiotic vs placebo[P=0.073,95%CI:-0.59(-1.23;0.05)].No statistically significant differences were reported in the evolution of bowel movement frequency and stool consistency between the groups.After 8 wk of supplementation,the overall QOL score was significantly higher in the Probiotic group than in the Placebo group[P=0.047,95%CI:3.86(0.52;7.20)].Furthermore,exploratory analyses showed statistically significant and clinically relevant improvements in QOL scores in abdominal pain responders vs nonresponders.CONCLUSION The results of this clinical study confirmed the abdominal pain alleviation properties of S.cerevisiae I-3856 in IBS-C.Abdominal pain relief was associated with improved QOL.ClinicalTrials.gov identifier:NCT03150212.

Treatment of Irritable Bowel Syndrome with a Combination of Curcumin, Green Tea and Selenomethionine Has a Positive Effect on Satisfaction with Bowel Habits

Background: Irritable bowel syndrome (IBS) is a common disorder impairing patient’s quality of life. Currently, there is no effective treatment for this syndrome. Coltect is a dietary supplement containing curcumin, green tea and selenomethionine. Aim: To investigate the effects of Coltect on IBS symptoms. Methods: A randomized, prospective, placebo-controlled, double blinded, crossover study. The study population included patients diagnosed with IBS by Rome criteria. Subjects were randomized to receive either Coltect or placebo for 4 weeks, and then received the opposite treatment for 4 weeks following a washout period of 2 weeks. The placebo was a pill, identical in color and size to the Coltect pill, with no active ingredients. Patients completed IBS health-related quality of life, severity score and IBS symptom questionnaires before and after each treatment period. Results: The study included 22 patients, ages 22 – 77 years. Coltect had a positive effect on patients’ satisfaction with their bowel habits (as measured on a scale from 0—Very satisfied to 100—Very unsatisfied). Average score was 70.4 ± 33.1 before and 61.8 ± 29.3 after Coltect treatment (p = 0.037). Other parameters, including abdominal pain, bloating, and effects of IBS on daily activity, symptoms, IBS-related quality of life and general health quality of life were unchanged. Conclusion: Coltect seems to have a positive effect on satisfaction with bowel habits.

Ehealth monitoring in irritable bowel syndrome patients treated with low fermentable oligo-, di-, mono-saccharides and polyols diet

In the present study we report on changes in irritable bowel syndrome-severity scoring system(IBS-SSS)and irritable bowel syndrome-quality of life(IBS-QoL)in 19 IBS patients,aged 18 to 74 years(F/M:14/5),during 12 wk registering their symptoms on the webapplication(www.ibs.constant-care.dk).During a control period of the first 6-wk patients were asked to register their IBS-SSS and IBS-QoL on the web-application weekly without receiving any intervention.Thereafter,low fermentable oligo-,di-,mono-saccharides and polyols(FODMAP)diet(LFD)was introduced for the next6 wk while continuing the registration.Though a small sample size a significant improvement in disease activity(IBS-SSS)was observed during both the control period,median:278(range:122-377),P=0.02,and subsequently during the LFD period,median:151(range:29-334),P<0.01.The IBS-QoL solely changed significantly during the LFD period,median:67(37-120),P<0.01.The significant reduction in disease activity during the control period shows a positive effect of the web-application on IBS symptoms when presented as a"traffic light".However adding the diet reduced IBSSSS to<150,inactive to mild symptoms.In the future results from larger scale trials are awaited.

Are bowel symptoms and psychosocial features different in irritable bowel syndrome patients with abdominal discomfort compared to abdominal pain?

BACKGROUND The Rome IV criteria eliminated abdominal discomfort for irritable bowel syndrome(IBS), which was previously included in Rome III. There are questions as to whether IBS patients with abdominal discomfort(seen in Rome III but not Rome IV) are different from those with abdominal pain(Rome IV).AIM To compare bowel symptoms and psychosocial features in IBS patients diagnosed with Rome III criteria with abdominal discomfort, abdominal pain, and pain &discomfort.METHODS We studied IBS patients meeting Rome III criteria. We administered the IBS symptom questionnaire, psychological status, and IBS quality of life. Patients were classified according to the predominant abdominal symptom associated with defecation into an only pain group, only discomfort group, and pain & discomfort group. We compared bowel symptoms, extraintestinal symptoms, IBS quality of life, psychological status and healthcare-seeking behaviors, and efficacy among the three groups. Finally, we tested risk factors for symptom reporting in IBS patients.RESULTS Of the 367 Rome III IBS patients enrolled, 33.8%(124 cases) failed to meet Rome IV criteria for an IBS diagnosis. There were no meaningful differences between the pain group(n = 233) and the discomfort group(n = 83) for the following:(1) Frequency of defecatory abdominal pain or discomfort;(2) Bowel habits;(3) Coexisting extragastrointestinal pain;(4) Comorbid anxiety and depression;and(5) IBS quality of life scores except more patients in the discomfort group reported mild symptom than the pain group(22.9% vs 9.0%). There is a significant tendency for patients to report their defecatory and non-defecatory abdominal symptom as pain alone, or discomfort alone, or pain & discomfort(all P < 0.001).CONCLUSION IBS patients with abdominal discomfort have similar bowel symptoms and psychosocial features to those with abdominal pain. IBS symptoms manifesting abdominal pain or discomfort may primarily be due to different sensation and reporting experience.

Assessment of the Efficacy of Rifaximin in the Management of Irritable Bowel Syndrome (IBS)

The aim of our study was to assess in our context, the efficacy of Rifaxim in improving the symptoms of irritable bowel syndrome particularly in its diarrheal (IBS-D) or mixed (IBS-DC) component and therefore assess its impact on patients’ quality of life. Patients and methods: This was an uncontrolled, non-comparative prospective cohort study of a single group of patients. Patients recruitment was done in two University Hospitals for 6 months (September 2015-February 2016). Were included ambulatory patients, male or female, aged 18 - 75 years, with diarrheic IBS (IBS-D) or mixed IBS (IBS-DC) diagnosed according to Rome III criteria and who agreed to participate in the study. Each patient received 400mg Rifaximin × 2/d for 15 days. The overall assessment of the efficacy of treatment at D15 (end of treatment) and D30 (2 weeks post-treatment) was the primary criterion of judgment. The statistical tests used were the Chi-square test and Fisher’s exact test for the qualitative variables and Student’s test for the quantitative variables. Results: A total number of 30 patients (16 women) with an average age of 44.5 ± 13.9 years were included. The overall assessment of symptoms by the patient with the Likert scale found 28 (93.3%) patients, 12 (40%) patients and 10 patients (33.3%) for a scale ≥2 at D0, D15 and D30 respectively. The assessment of the intensity of pain or abdominal discomfort found at D0, D15 and D30 respectively: 27(90%), 13(43.4%) and 6(20.1%) patients who had an EVA score > 2. The mean score for Francis to assess the improved quality of life was 247.1 ± 97.4 at D0, 99.8 ± 63.1 at D15 and 128.8 ± 70.6 at D30. Conclusion: There is a good overall improvement of symptoms in our patients suffering from IBS-D or mixed (IBS-DC) on Rifaximin with improvement of the quality of life.

温肾健脾法联合耳穴埋豆对腹泻型肠易激综合征的疗效观察

目的探讨温肾健脾法联合耳穴埋豆对腹泻型肠易激综合征(diarrhea-predominant irritable bowel syndrome,IBS-D)患者的临床疗效。方法选择中国中医科学院望京医院于2020年6月—2022年6月收治的IBS-D患者104例为研究对象,依据随机数表法,分为对照组和观察组各52例。对照组接受温肾健脾法治疗,观察组在对照组的基础上接受耳穴埋豆。治疗4周后,比较两组临床疗效、症状评分、肠易激综合征生活质量评分(irritable bowel syndrome-quality of life,IBS-QOL)及胃肠激素[包括血清5-羟色胺(5-hydroxy tryptamine,5-HT)、血管活性肠肽(vasoactive intestinal peptide,VIP)、P物质(substance P,SP)、生长抑素(somatostatin,SS)、胆囊收缩素(cholecystokinin,CCK)]水平。结果观察组总有效率明显高于对照组,差异有统计学意义(P<0.05);治疗前,两组症状及IBS-QOL评分相比,差异无统计学意义(P>0.05);治疗后,两组症状评分明显低于治疗前,IBS-QOL评分明显高于治疗前,且观察组症状评分明显低于对照组,IBS-QOL评分明显高于对照组,差异有统计学意义(P<0.05);治疗前,两组5-HT、VIP、SP、SS、CCK水平相比,差异无统计学意义(P>0.05);治疗后,观察组5-HT、VIP、SP、CCK水平明显低于对照组,SS水平明显高于对照组,差异有统计学意义(P<0.05)。结论温肾健脾法联合耳穴埋豆应用于IBS-D患者可显著提升临床疗效,改善症状及生活质量评分,同时还能有效改善胃肠激素水平,值得推广应用。

穴位埋线治疗便秘型肠易激综合征的疗效观察及对血清SP含量的影响

目的观察穴位埋线治疗便秘型肠易激综合征(constipation-predominant irritable bowel syndrome,IBS-C)的临床疗效及对血清P物质(substance P,SP)含量的影响。方法43例IBS-C患者随机分为观察组(22例)和对照组(21例)。观察组采用埋线方法治疗,对照组采用枸橼酸莫沙必利分散片治疗。观察两组治疗前后及随访期肠易激综合征症状严重程度量表(IBS symptom severity scale,IBS-SSS)评分、肠易激综合征生活质量量表(irritable bowel syndrome quality of life,IBS-QOL)评分和焦虑自评量表(self-rating anxiety scale,SAS)评分的变化及治疗前后血清SP含量变化。结果观察组治疗后及随访期IBS-SSS各项评分与总评分较治疗前降低(P<0.05),随访期IBS-SSS各项评分与总评分较治疗后升高(P<0.05);对照组治疗后IBS-SSS各项评分与总评分较治疗前降低(P<0.05),随访期IBS-SSS各项评分与总分较治疗后升高(P<0.05);观察组治疗后和随访期腹痛不适评分低于对照组(P<0.05)。两组治疗后及随访期IBS-QOL总评分高于治疗前,两组随访期IBS-QOL评分低于治疗后,差异有统计学意义(P<0.05);观察组治疗后及随访期IBS-QOL评分高于对照组(P<0.05)。观察组治疗后及随访期SAS评分均降低(P<0.05),随访期SAS评分高于治疗后(P<0.05);对照组治疗后SAS评分低于治疗前(P<0.05),随访期SAS评分高于治疗后(P<0.05);观察组治疗后及随访期SAS评分均低于对照组(P<0.05)。两组治疗后血清SP含量均降低(P<0.05);观察组血清SP含量低于对照组(P<0.05)。观察组临床疗效高于对照组,差异具有统计学意义(P<0.05)。结论穴位埋线和枸橼酸莫沙必利分散片均能缓解IBS-C患者临床症状,提高其生活质量,但穴位埋线相较于枸橼酸莫沙必利分散片临床疗效更稳定和持久;在改善腹痛和生活质量方面穴位埋线的远期效应更优。穴位埋线治疗IBS-C的作用机制可能与下调血清SP含量密切相关。

慢性病病人生命质量测定量表体系之肠易激综合征量表QLICD-IBS(V2.0)的条目筛选

目的筛选出符合国情的第二版慢性病病人生命质量测定量表体系之肠易激综合征量表QLICD-IBS(V2.0)的特异模块的条目。方法运用议题小组和核心小组分工合作的方法构建出条目池,并对条目进行初步评价、修改和筛选形成初步量表。随后,分别抽取2020年11月至2021年2月昆明医科大学第一附属医院40例肠易激综合征病人和昆明医科大学第一附属医院、第二附属医院40名医护人员进行问卷调查和访谈,采用医生重要性评分、相关系数法、变异度法、因子分析法和克朗巴赫系数法5种方法对条目进行筛选,结合专家讨论对条目进行再次筛选。结果定性和定量分析结合讨论后,最终选定13个条目为QLICD-IBS(V2.0)量表的特异模块,包含疾病症状、治疗副作用及心理生活影响3个侧面。结论QLICD-IBS(V2.0)量表的特异模块是严格按照量表开发和筛选步骤和方法完成的,具有较好的内容效度和代表性。

根除幽门螺杆菌治疗对便秘型肠易激综合征患者胃肠道激素水平及生活质量的影响

目的探讨幽门螺杆菌(Hp)感染对便秘型肠易激综合征(IBS-C)患者胃肠激素水平及生活质量的影响。方法回顾性选取2021年7月至2022年6月广州市红十字会医院收治的158例IBS-C且14C呼气试验阳性患者为研究对象,根据是否接受根除Hp治疗分为对照组(64例)和观察组(94例)。对照组给予常规治疗,观察组在常规治疗的基础上予根除Hp治疗。比较两组患者治疗前后的生长抑素(SS)、血浆胃动素(MTL)、胃泌素-17(G-17)以及血管活性肠肽(VIP)水平及肠易激综合征生活质量量表(IBS-QOL)评分。结果治疗前,观察组与对照组患者的胃肠激素水平及IBS-QOL评分比较,差异无统计学意义(P>0.05)。两组患者治疗后的SS、G-17及VIP水平低于治疗前,MTL水平高于治疗前,差异有统计学意义(P<0.05)。治疗后,观察组患者的SS、G-17及VIP水平低于对照组,MTL水平高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组患者的IBS-QOL各维度评分及总分高于对照组,差异有统计学意义(P<0.05)。结论Hp感染可能与IBS-C发病相关,根除Hp治疗可调节胃肠道激素水平,有助于提高此类患者生活质量。

腹泻型肠易激综合征患者症状、生活质量与心理防御机制的相关性分析

目的 探讨腹泻型肠易激综合征(diarrhea-predominant irritable bowel syndrome,IBS-D)患者症状、生活质量(quality of life,QOL)与心理防御机制的相关性。方法 选取2020年4月至2022年12月首都医科大学附属北京世纪坛医院IBS-D患者59例(IBS-D组)和邻近社区的健康人群41例(对照组)。采用精神疾病诊断与统计手册(the diagnostic and statistical manual of mental disorder,DSM-Ⅳ版)和国际神经精神访谈工具(mini-international neuropsychiatric interview,MINI)对IBS-D组患者进行访谈,采用症状严重程度(severity scale,SS)问卷和QOL问卷分别评估IBS-D患者10 d内症状的严重程度和QOL,采用心理防御方式(defense style,DS)问卷评价两组研究对象面对心理压力时采用的心理防御机制,采用spearman相关分析IBS-D患者症状、QOL与心理防御机制的相关性。结果 100例研究对象中男32例、女68例;年龄26~73岁、平均(50.1±12.5)岁。两组性别、年龄和教育年限的差异无统计学意义(P>0.05)。与对照组相比,IBS-D组的不成熟型防御方式(投射、被动攻击、潜意显现、抱怨、幻想、退缩、躯体化),成熟型防御方式(压抑)和中间型防御方式(反向形成、制止、理想化、伴无能之全能、隔离、同一化、否认、消耗倾向、期望)评分较高,差异有统计学意义(P <0.05)。Spearman相关分析结果显示,IBS-D组防御方式得分与SS得分和QOL均无相关性(P> 0.05)。结论IBS-D患者更多使用多种不成熟的心理防御方式应对情绪冲突和外部压力。IBS-D患者的症状、生活质量与具体心理防御方式无相关性。

参苓白术散加减对腹泻型肠易激综合征脾虚湿盛证患者血清胃肠激素水平的影响

目的探讨腹泻型肠易激综合征(IBS-D)脾虚湿盛证患者应用参苓白术散加减治疗的效果。方法选取2020年10月至2022年10月该院收治的78例IBS-D脾虚湿盛证患者为研究对象,按照随机数字表法分为观察组与对照组,各39例。对照组采用匹维溴铵治疗,观察组联合参苓白术散加减治疗,均连续治疗4周。比较两组总有效率、降钙素基因相关肽(CGRP)、血管活性肠肽(VIP)、5-羟色胺(5-HT)、胆囊收缩素(CCK)水平,以及中医证候总积分、生活质量、不良反应。结果治疗前,观察组与对照组CGRP、VIP、5-HT、CCK水平,中医证候总积分,IBS生活质量量表(IBS-QOL)评分比较,差异无统计学意义(P>0.05)。治疗后,观察组总有效率(94.87%)高于对照组(79.92%),CGRP、VIP、5-HT、CCK水平及中医证候总积分均低于对照组,IBS-QOL评分高于观察组,差异均有统计学意义(P<0.05)。两组均未见明显不良反应。结论匹维溴铵治疗基础上联合参苓白术散加减治疗IBS-D脾虚湿盛证患者效果确切,且具有良好的安全性,值得临床推广应用。

Chronic gastrointestinal symptoms and quality of life in the Korean population

AIM: To evaluate the prevalence of chronic gastroin-testinal symptoms and their impact on health-related quality of life (HRQOL) in the Korean population. METHODS: A cross-sectional survey, using a reliable and valid Rome Ⅱ based questionnaire, was per-formed on randomly selected residents, between 18 and 69 years in age. All respondents were interviewed at their homes or offices by a team of interviewers. The impact of chronic gastrointestinal symptoms on HRQOL was assessed using the Korean version of the 36-item Short-Form general health survey (SF-36). RESULTS: Of the 1807 eligible subjects, 1417 (78.4%: male 762; female 655) were surveyed. Out of the respondents, 18.6% exhibited at least one chronic gastrointestinal symptom. The prevalence of gastro- esophageal reflux disease (GERD), defined as heart- burn and/or acid regurgitation experienced at least weekly, was 3.5% (95% CI, 2.6-4.5). The prevalence of uninvestigated dyspepsia, irritable bowel syndrome (IBS) and chronic constipation based on Rome Ⅱ cri- teria were 11.7% (95% CI, 10.1-13.5), 2.2% (95%CI, 1.5-3.1), and 2.6% (95% CI, 1.8-3.5) respectively. Compared with subjects without chronic gastrointesti- nal symptoms (n = 1153), those with GERD (n = 50), uninvestigated dyspepsia (n = 166) and IBS (n = 31) had signifi cantly worse scores on most domains of the SF-36 scales. CONCLUSION: The prevalence of GERD, uninvesti-gated dyspepsia and IBS were 3.5%, 11.7% and 2.2% respectively, in the Korean population. The health- related quality of life was signifi cantly impaired in sub-jects with GERD, uninvestigated dyspepsia and IBS in this community.

认知行为疗法联合药物治疗肠易激综合征的效果及对患者焦虑、抑郁情绪的影响

目的探讨认知行为疗法(CBT)联合药物治疗肠易激综合征(IBS)的效果及对患者焦虑、抑郁情绪的影响。方法选取2020年1月至2022年6月我院消化内科门诊收治的96例IBS患者为研究对象,按照随机数字表法将其分为对照组和观察组,各48例。对照组给予药物治疗,观察组在对照组基础上给予CBT治疗。比较两组的症状改善时间、IBS症状严重程度量表(IBS-SSS)及IBS生活质量量表(IBS-QOL)评分、临床疗效、焦虑、抑郁情绪及复发率。结果观察组的腹痛、腹胀、腹部不适、排便异常改善时间短于对照组,差异具有统计学意义(P<0.05)。治疗前,两组的IBS-SSS、IBS-QOL评分比较,差异无统计学意义(P>0.05);治疗后,两组的IBS-SSS、IBS-QOL评分均降低,且观察组低于对照组,差异具有统计学意义(P<0.05)。观察组的治疗总有效率为93.75%,高于对照组的79.17%,差异具有统计学意义(P<0.05)。治疗前,两组的焦虑自评量表(SAS)、抑郁自评量表(SDS)评分比较,差异无统计学意义(P>0.05);治疗后,两组的SAS、SDS评分均降低,且观察组低于对照组,差异具有统计学意义(P<0.05)。观察组的复发率为8.33%,低于对照组的43.75%,差异具有统计学意义(P<0.05)。结论CBT联合药物治疗能够缓解IBS患者的临床症状,提高生活质量,降低复发率,改善焦虑、抑郁情绪,临床疗效较好。